John Bell
Sir John Irving Bell is Regius Professor of Medicine at University of Oxford. John Bell is a Canadian immunologist and geneticist. From 2006 to 2011, he was President of the Academy of Medical Sciences, and since 2002 he has held the Regius Chair of Medicine at the University of Oxford, UK. He has been Chairman of OSCHR since 2006. Bell was born in Edmonton, Alberta, where his parents worked in haematology and pharmacy. He attended Ridley College in St. Catharines, Canada. He graduated from the University of Alberta in 1975, and then studied medicine on a Rhodes Scholarship at the University of Oxford. In 1982, he took up a position as Clinical Fellow in Immunology with Hugh McDevitt at Stanford University, California, USA, where he worked on histocompatibility antigens and autoimmune disease. In 1987 Bell returned to Oxford as a Wellcome Trust Senior Clinical Fellow, and joined the Institute of Molecular Medicine, founded by David Weatherall. In 1992 he succeeded Weatherall as the Nuffield Professor of Clinical Medicine and, in 2002, became the Regius Professor of Medicine at Oxford, also after Weatherall. In 1994, Bell was one of the founders of the Wellcome Trust Centre for Human Genetics at Oxford University. He is an emeritus fellow of Magdalen College, Oxford and a Student of Christ Church, Oxford. He sat on the Council of the Medical Research Council 1998–2003. Since 2011, Bell has been one of two Life Sciences Champions for the UK, reporting to the Prime Minister.
Bell has been a non-executive director of Roche since 2001. A BMJ campaign to make the results of unpublished studies on the anti-influenza drug oseltamivir (Tamiflu) available to researchers led to the journal's editor Fiona Godlee urging Bell "as an internationally respected scientist and clinician and a leader of clinical research in the United Kingdom, to bring your influence to bear on your colleagues on Roche's board." Roche subsequently agreed to a wide policy of data transparency in clinical trials. Matthew Thompson and Carl Heneghan wrote in a letter to the journal "...according to Roche's 2011 financial report, John Bell received 390 000 Swiss Francs (£260 450; €322 450; $420 000) last year for his role on the board of directors. What do Roche and its shareholders expect for this level of involvement and remuneration?" The House of Commons Science and Technology Committee report on the subject broadly supported the release of more clinical trial data but urged caution on public release of individual patient data. Bell serves on the Genentech Board in San Francisco, and formerly served on the scientific advisory board of AstraZeneca (1997–2000). He was the founding director of three biotechnology companies, including Oxagen, Avidex, and Powderject and is also on the Board of Atopix. His charity positions include chairing the board of trustees of the Oxford Health Alliance and the science committee of the UK Biobank. He chairs the Global Health Scientific advisory board of the Bill & Melinda Gates Foundation, he is a Trustee of the Rhodes Trust, he sits on the award jury of the Gairdner Foundation, he is a non-executive member of Genomics England, and he is a member of Cancer Research UK. He has advised governments and foundations in Singapore, France, Canada, Sweden, Finland, and Alberta on biomedical research. He is on the Jenner Institute Board and the Gray Institute Board. He is on the advisory Board for the McGill Genomics Institute and the Montreal Neurological Institute, and chairs the advisory board for the Oak Foundation and the Robertson Foundation. He attended the 2013 Bilderberg Group conference.
Bell's research has identified genes involved in susceptibility to diabetes mellitus type 1 and rheumatoid arthritis and multiple sclerosis. His work has been important in elucidating the interactions on the surface of the T cell involved in immune activation. He has also worked on the biomedical applications of high-throughput genomic technologies, including structural genomics and ENU mutagenesis. He has been directly involved in applying genetics in a clinical settings and helped developed the 100,000 genome project in England.
Regarding Sir John Bell's work on COVID-19 at Oxford University, is one of the leading efforts underway to develop a vaccine.
Bell has been a non-executive director of Roche since 2001. A BMJ campaign to make the results of unpublished studies on the anti-influenza drug oseltamivir (Tamiflu) available to researchers led to the journal's editor Fiona Godlee urging Bell "as an internationally respected scientist and clinician and a leader of clinical research in the United Kingdom, to bring your influence to bear on your colleagues on Roche's board." Roche subsequently agreed to a wide policy of data transparency in clinical trials. Matthew Thompson and Carl Heneghan wrote in a letter to the journal "...according to Roche's 2011 financial report, John Bell received 390 000 Swiss Francs (£260 450; €322 450; $420 000) last year for his role on the board of directors. What do Roche and its shareholders expect for this level of involvement and remuneration?" The House of Commons Science and Technology Committee report on the subject broadly supported the release of more clinical trial data but urged caution on public release of individual patient data. Bell serves on the Genentech Board in San Francisco, and formerly served on the scientific advisory board of AstraZeneca (1997–2000). He was the founding director of three biotechnology companies, including Oxagen, Avidex, and Powderject and is also on the Board of Atopix. His charity positions include chairing the board of trustees of the Oxford Health Alliance and the science committee of the UK Biobank. He chairs the Global Health Scientific advisory board of the Bill & Melinda Gates Foundation, he is a Trustee of the Rhodes Trust, he sits on the award jury of the Gairdner Foundation, he is a non-executive member of Genomics England, and he is a member of Cancer Research UK. He has advised governments and foundations in Singapore, France, Canada, Sweden, Finland, and Alberta on biomedical research. He is on the Jenner Institute Board and the Gray Institute Board. He is on the advisory Board for the McGill Genomics Institute and the Montreal Neurological Institute, and chairs the advisory board for the Oak Foundation and the Robertson Foundation. He attended the 2013 Bilderberg Group conference.
Bell's research has identified genes involved in susceptibility to diabetes mellitus type 1 and rheumatoid arthritis and multiple sclerosis. His work has been important in elucidating the interactions on the surface of the T cell involved in immune activation. He has also worked on the biomedical applications of high-throughput genomic technologies, including structural genomics and ENU mutagenesis. He has been directly involved in applying genetics in a clinical settings and helped developed the 100,000 genome project in England.
Regarding Sir John Bell's work on COVID-19 at Oxford University, is one of the leading efforts underway to develop a vaccine.